4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-22-046909
Chief R&D Officer sold 73,716 shares at $4.65 ($342,779)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2022-08-18 | Sale | −73,716 | $4.65 | $342,779 | 327,123 | D |
| Open-market sales · 73,716 sh · avg $4.65 · $342,779 | |||||||
Loading xslF345X03/doc4.xml…